Genmab And Lundbeck Amlenetug Data Adds Nuance To Valuation Debate [Yahoo! Finance]
Genmab A/S - American Depositary Shares (GMAB)
Company Research
Source: Yahoo! Finance
Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Genmab and Lundbeck shared new clinical progress for amlenetug at the AD/PD 2026 conference. Amlenetug is a human monoclonal antibody targeting synucleinopathies such as multiple system atrophy and Parkinson's disease. The update focused on emerging clinical data and development advances for this investigational neurological therapy. For investors tracking CPSE:GMAB, the latest amlenetug update adds additional detail to Genmab's work in severe neurological diseases. The company's shares trade at DKK1,645.0, with a mixed return profile, including a 19.9% gain over 1 year and a 35.5% decline over 3 years. That context can help frame how new clinical data may relate to an already volatile share price history. These developments around amlenetug provide another concrete data point to monitor as Genmab expands beyond its established oncology focus into neurology. Future clinical readouts, re
Show less
Read more
Impact Snapshot
Event Time:
GMAB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GMAB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GMAB alerts
High impacting Genmab A/S - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
GMAB
News
- Constitution of the Board of Directors in Genmab A/S and Grant of Restricted Stock Units and Warrants to Employees in Genmab [Yahoo! Finance]Yahoo! Finance
- Genmab A/S Touts Strong 2025, Teases Catalyst-Heavy 2026 With Potential 2027 Launches [Yahoo! Finance]Yahoo! Finance
- Genmab A/S (GMAB) Presents at Barclays 28th Annual Global Healthcare Conference Transcript [Seeking Alpha]Seeking Alpha
- Genmab A/S (GMAB) is now covered by Wells Fargo & Company. They set an "overweight" rating and a $40.00 price target on the stock.MarketBeat
- Transactions in Connection with Share Buy-back Program [Yahoo! Finance]Yahoo! Finance